Cereplast, Inc., a pioneer in the manufacture of plastics which derive largely from resins based on plant starches, released news announcing projections for its market sector.

Expecting a ten-fold sales increase in the U.S. bio-plastics market by 2020, the Company cited the $1B sales figures from 2007 and estimates which show that, within ten years, bio-plastics could represent up to an astonishing 30% of the total plastics market.

With the Obama administration leaning heavily toward a green economy and increasing demand from consumers for biodegradable products, Cereplast is poised to cash in on the “green” economy and return substantial value to its investors. Through its proprietary technology and manufacturing know how, Cereplast is ready to capture the explosive growth of this sector, with offerings like Cereplast Compostables® and Cereplast Hybrids®, which are certified compostable in the U.S. and Europe.

CEO and founder of Cereplast, Frederic Scheer, spoke of their breakthrough

...

Digital River, Inc. (DRIV) recently reported third-quarter revenues of $99.4 million, up 3.2% from the year-ago level and surpassed management’s revenue guidance of $96.5 million – $98.5 million. The growth in revenues was driven by strength in software, consumer electronics and games markets where the company expanded existing client relationships and closed new business as well. Earnings per share of 42 cents easily beat the Zacks Consensus Estimate of 33 cents and exceeded management’s forecast of 38 cents – 41 cents. Earlier, prime customer Symantec announced that it would not renew its existing e-commerce agreement with Digital River beyond June 30, 2010, when its existing contract expires. However, management is encouraged by the future prospects of its existing business. Going forward, management continues to work on its business plans in response to Symantec’s decision to not renew its e-commerce contract. The company stated that it does

...

Diodes Inc. (DIOD) posted third quarter results after the closing bell on Monday. The company swung to a GAAP net profit of $7.0 million, from GAAP net loss of $3.0 million and $4.6 million in the previous and year-ago quarters, respectively. Excluding certain special items, pro forma earnings per share came in at 21 cents, edging past the Zacks Consensus Estimate by a penny.   Diodes is a global designer, manufacturer and supplier of application specific standard products serving the consumer electronics, computing, communications, industrial and automotive markets. The company’s product portfolio includes diodes, rectifiers, transistors, MOSFETs, protection devices, functional specific arrays, amplifiers and comparators, Hall-effect sensors, temperature sensors and power management devices.   The company reported an 8.9% year-over-year decline in revenues to $122.1 million, but grew by 17.5% on a sequential basis. The sequential expansion was driven by a recovery in the demand for Diodes’ products ...

Molex Inc.’s (MOLX) earnings per share for the fiscal first quarter beat the Zacks Consensus Estimate by 2 cents. Revenues beat the consensus by 2%.   Revenues   Revenues of $674.0 million was up 18.1% sequentially and down 19.7% year over year. This is the second quarter of double-digit sequential growth and fourth quarter of year-over-year decline. The recession has impacted the connector industry, which is expected to decline 25% in calendar year 2009. The company generates the bulk of its revenue from the connector market, so results have been strongly impacted by the recession. However, as the sequential increases indicate, it is past the bottom. The company saw particular strength in the data, consumer electronics and telecom markets.   The geographical distribution of revenues indicates that the company generates the largest chunk of its sales from Asia Pacific countries (around 54% of total fiscal 2009 revenues). The ...

Rent-A-Center, Inc. (RCII), the largest rent-to-own operator, recently posted third-quarter earnings of 55 cents per share, which surpassed the Zacks Consensus Estimate of 50 cents. EPS results climbed 25% from 44 cents delivered in the prior-year quarter buoyed by stringent cost-control measures.   Management expects fourth-quarter earnings in the range of 55 cents to 61 cents per share. For fiscal 2010, earnings is projected between $2.30 and $2.50 per share. The Zacks Consensus Estimate for the fourth quarter and fiscal year are 58 cents and $2.50 per share, respectively.   Total revenue tumbled 5.3% year-over-year to $671.3 million due to 6.1% decline in comparable-store sales. Management expects comps to fall between 3% and 5% for fourth-quarter 2009, and to be flat for fiscal year 2010.   Total revenues are expected in the range of $662 million to $677 million for fourth quarter and between $2.7 billion and $2.8 ...

NetFlix Inc.’s (NFLX) third-quarter adjusted earnings outperformed the Zacks Consensus Estimate of 45 cents per share. The company announced a 44.9% increase in non-GAAP net income to $32.1 million or 55 cents per share for the quarter, up from $22.1 million or 36 cents per share in the same quarter a year ago.   However, net income fell 6.9% from $34.4 million or 58 cents per share in the last quarter. This was due to sequentially higher operating expenses in the quarter, which were up 13%. Operating expenses, as a percentage of revenues, stood at 23.3% in the quarter versus 21.2% in the previous quarter. Although operating expenses increased 19.1% year over year, they declined as a percentage of revenues from 24.2% in the same quarter a year ago.   Total revenues for the quarter increased 24% year over year and 3.6% sequentially to $423.1 million. As a ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 19, 2009

DrStockPick.com Stock Report!

AMGN, PWRM, JNJ, CSRH, GE, CVAT, TEVA, AQNM

**************************************************************

AMGN, Amgen Inc.

AMGN, a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.

The Food and Drug Administration wants more information about AMGN’s osteoporosis treatment Prolia before granting marketing approval. It delays a drug seen as a potential blockbuster for the company.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of

...

For the second quarter of fiscal 2010, Audiovox Corp. (VOXX) reported net income of $2.8 million or earnings per share of 12 cents, compared to a net loss of $2.3 million or a loss per share of 10 cents in the corresponding prior-year period. This exceeded the Zacks Consensus Estimate of 2 cents per share. Net sales for the quarter were $124.9 million, compared to net sales of $147.2 million in the prior-year period, a decrease of 15.2%. Accessories sales were $45.9 million, an increase of 29% compared to $35.5 million in the same quarter, a year ago. This increase is primarily due to the addition of new customers and higher sales of antennas as a result of the switch from analog to digital TV, remote controls and other accessory lines under Terk, Acoustic Research and RCA. Electronics sales, which include both mobile and consumer ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

 

Friday September 18, 2009

DrStockPick.com Stock Report!

PWRM, IBM, NWMT, CVAT, CSRH, F, AQNM, NVS

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3

...

DrStockPick.com Stock Report!

Thursday September 10, 2009

**************************************************************

Concurrent (Nasdaq: CCUR), a worldwide leader in video and media data and advertising solutions, is announcing the international extension of its three-screen strategy to bring open, commercial and intelligent video solutions to television, personal computers and mobile devices. First announced in the U.S. in March 2009, Concurrent’s strategy now leverages the company’s technological expertise to enable its customers to deliver, monetize and drive the future of video around the globe.

Diguang International Development Co., Ltd. (OTC Bulletin Board: DGNG) today announced that Shenzhen Diguang Electronics Co., Ltd. (”Diguang”) was selected as a member of the Standard

...